London, 18 November 2026 – The Embassy of Italy in London hosted “Italian Life Sciences on the Global Stage” at Casa Italia on 17 November 2026. The event was organised with investment banking firm Jefferies and promoted by the Italian Ministry of Foreign Affairs and International Cooperation (MAECI). It brought together more than 100 representatives from Italian pharmaceutical and life sciences groups, international biopharma companies and investors to discuss the rapid growth of Italy’s life sciences ecosystem.
The evening was the London stage of the Montalcini Global Biotech Tour, the initiative run by the Ministry of Foreign Affairs in collaboration with the Italian Trade Agency (ITA) that showcases the excellencies of Italy’s biotech and life sciences sector and exposes them to the world’s leading industry hubs. Named after Nobel laureate Rita Levi-Montalcini, the Tour was launched in January 2025 in San Francisco. It has since toured in Doha, Basel, Boston, Vienna, San Diego, and Cologne.
The event took place during the Jefferies Global Healthcare Conference, Europe’s largest healthcare investment conference, which gathers listed and private healthcare companies and international investors in London every November. Holding the event that evening put Italian companies in front of the global capital in town for the conference and gave investors a direct view of the Italian ecosystem.
It was also the fifth event of The Pulse of Progress – Italian Ideas that Transform, the series launched by the Embassy to promote Italian innovation in the United Kingdom. It follows two events on artificial intelligence, one on tech education and one on startups.
Italian companies growing worldwide
After welcoming remarks by Ambassador Fabio Cassese, Andrea Bracchi from Jefferies gave an overview of the Italian M&A ecosystem. A first session, “Italian Life Sciences – From Innovation to Global Scale”, featured Italian companies that have grown internationally, including in the UK:
- Laura Vergani, SVP Global Communications & Public Affairs, Chiesi
- Marco Campione, President and CEO, Blue Earth Diagnostics – Bracco
- Emanuele Degortes, Global Head of Access Policy, Patient Advocacy & Engagement, Menarini
The speakers showed how Italian life sciences companies have grown from strong domestic roots into global players, investing in research, manufacturing and commercial operations abroad. They pointed to the United Kingdom as a key market and a natural partner for innovation.
Italy as a destination for international investments
The panel “Italy as a Hub for Life Sciences Investments” turned to the other side of the story: international groups and investors choosing Italy for research, manufacturing and capital deployment. It brought together:
- Alessandro De Venuto, Government Affairs National Policy Lead, GSK
- Marco Dieci, Senior Partner, CDP Venture Capital
- Dimitrios Tzivelis, Managing Director, Permira
- Riccardo Zagaria, President of Egualia and CEO of DOC Pharma
The discussion was moderated by Massimiliano Rubin, Vice President, Head of Financial Institutions at IQVIA. Panellists discussed what makes Italy attractive to international investors, from the quality of its research and talent-pool to its advanced manufacturing base and a growing venture capital ecosystem. They also looked at what is needed for Italian companies to scale up further.
Fabio Cassese, Ambassador of Italy to the United Kingdom, said: “Life sciences are among the strongest engines of the Italian economy, and our companies are increasingly global players. Bringing the Montalcini Global Biotech Tour to London, in the very week when the world’s healthcare investors meet here, means taking Italian excellence where partnerships and capital are built. This event told one story from two sides: Italian companies growing in the United Kingdom and worldwide, and international groups choosing Italy to research, manufacture and invest. This is exactly the spirit of The Pulse of Progress: Italian ideas that transform.”
Andrea Bracchi, Head of Italian M&A at Jefferies, said: “We were delighted to partner with the Embassy of Italy to bring the Montalcini Global Biotech Tour to London and to welcome such strong participation from across the Italian and international life sciences communities. Rita Levi-Montalcini’s extraordinary story, from her pioneering discovery of Nerve Growth Factor to its translation decades later into innovative treatments, is a powerful example of the ability of Italian science to have a lasting impact on patients around the world.”
Marco Baruzzi, Director in Healthcare Investment Banking at Jefferies, said “Over the past 17 years, the Jefferies Global Healthcare Conference has grown into one of the defining gatherings of the global healthcare calendar. This year, we welcomed more than 1,100 companies and 1,700 investors, hosted over 360 presentations and facilitated more than 22,500 meetings. Bringing the Montalcini Global Biotech Tour into this global forum provided an opportunity to showcase the strength and ambition of Italian life sciences to the companies, investors and industry leaders shaping the future of healthcare.”
